Searle & Co’s Antares Pharma, Inc. ATRS Stock Holding History

Searle & Co’s Portfolio ATRS Stock Details ATRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-20,000	Closed	-$66K	–	138
2019 Q2	$66K	Hold	20,000	–	–	0.04%	128
2019 Q1	$61K	Buy	+20,000	New	+$64.8K	0.04%	125

Other funds holding ATRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

MWP

MYCIO Wealth Partners Philadelphia, Pennsylvania $502M AUM 11.65% 1-Year Est. Return

Searle & Co's ATRS Position: Q3 2019 in Review

Searle & Co sold out of Antares Pharma, Inc. (ATRS) in Q3 2019, closing a stake of 20,000 shares — an estimated $66K sold.

Searle & Co first reported a position in ATRS in Q1 2019 and held it in 2 quarters. The position peaked at $66K in Q2 2019. 135 funds tracked by Wall St. Rank hold ATRS as of Q3 2019.

Searle & Co reported no remaining Antares Pharma, Inc. position as of Q3 2019 after selling out during the quarter.
Searle & Co sold 20,000 Antares Pharma, Inc. shares in Q3 2019, an estimated $66K.
Searle & Co first reported a position in Antares Pharma, Inc. in Q1 2019 and held it in 2 quarters.
Searle & Co's Antares Pharma, Inc. position peaked at $66K in Q2 2019.
135 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q3 2019.

Based on Searle & Co's 13F filing for Q3 2019, filed 22 Oct 2019.